Vanguard Group Inc. Has $183.03 Million Stock Position in Scholar Rock Holding Corporation $SRRK

Vanguard Group Inc. lifted its stake in Scholar Rock Holding Corporation (NASDAQ:SRRK) by 1.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,914,927 shares of the company’s stock after purchasing an additional 53,333 shares during the period. Vanguard Group Inc. owned 5.11% of Scholar Rock worth $183,032,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Norges Bank bought a new stake in shares of Scholar Rock during the second quarter worth approximately $41,628,000. Balyasny Asset Management L.P. acquired a new position in shares of Scholar Rock in the 2nd quarter valued at $33,062,000. Federated Hermes Inc. lifted its stake in shares of Scholar Rock by 232.1% in the 3rd quarter. Federated Hermes Inc. now owns 800,455 shares of the company’s stock valued at $29,809,000 after purchasing an additional 559,455 shares during the period. Bellevue Group AG boosted its position in shares of Scholar Rock by 17.6% in the 2nd quarter. Bellevue Group AG now owns 2,947,295 shares of the company’s stock worth $104,393,000 after purchasing an additional 440,405 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Scholar Rock by 161.0% during the third quarter. JPMorgan Chase & Co. now owns 713,988 shares of the company’s stock worth $26,589,000 after purchasing an additional 440,401 shares during the period. 91.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Scholar Rock

In related news, General Counsel Junlin Ho sold 9,580 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total value of $445,757.40. Following the completion of the transaction, the general counsel directly owned 241,545 shares of the company’s stock, valued at approximately $11,239,088.85. This trade represents a 3.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mo Qatanani sold 8,484 shares of Scholar Rock stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $47.07, for a total transaction of $399,341.88. Following the completion of the transaction, the insider owned 98,445 shares of the company’s stock, valued at $4,633,806.15. This represents a 7.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 344,932 shares of company stock worth $15,371,225. 13.30% of the stock is currently owned by company insiders.

Scholar Rock Stock Performance

NASDAQ:SRRK opened at $43.48 on Tuesday. The company has a market capitalization of $4.44 billion, a P/E ratio of -13.80 and a beta of 0.70. The business has a fifty day simple moving average of $45.32 and a two-hundred day simple moving average of $38.99. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.30 and a quick ratio of 6.30. Scholar Rock Holding Corporation has a 1 year low of $22.71 and a 1 year high of $49.82.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). On average, analysts expect that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on SRRK shares. Citigroup began coverage on shares of Scholar Rock in a report on Friday, January 9th. They issued a “buy” rating and a $55.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Scholar Rock in a report on Thursday, January 22nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Scholar Rock in a research report on Thursday, December 11th. BMO Capital Markets reissued an “outperform” rating and set a $50.00 target price on shares of Scholar Rock in a research report on Friday, November 14th. Finally, HC Wainwright boosted their price objective on Scholar Rock from $44.00 to $58.00 and gave the company a “buy” rating in a report on Monday, January 26th. Four analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $51.14.

Scholar Rock Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).